SEATTLE, Aug. 13 /PRNewswire-FirstCall/ -- Trubion
Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced that it plans
to issue earnings results for the second quarter and first six
months ended June 30, 2010, after the
close of market on Aug. 16, 2010. The
company's earnings conference call will take place Aug. 16, 2010, at 2 p.m.
Pacific Time, 5 p.m. Eastern
Time.
(Logo:
http://photos.prnewswire.com/prnh/20090320/TRUBIONLOGO)
(Logo:
http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)
Both live events will be available for viewing on Trubion's
website at http://investors.trubion.com.
Second-Quarter and First Six Months 2010 Conference Call:
2 p.m. PDT/5
p.m. EDT, Aug. 16, 2010
Trubion will host a conference call and webcast to discuss its
second quarter and six months ended 2010 financial results and
provide an update on business activities. The call will be held
Aug. 16 at 2
p.m. Pacific Time, 5 p.m. Eastern
Time. The live event will be available from Trubion's
website at http://investors.trubion.com, or by calling (877)
564-1186 or (973) 409-9686. A replay of the discussion will be
available beginning 8 p.m. Eastern
Time from Trubion's website or by calling (800) 642-1687 or
(706) 645-9291 and entering 93177343. The telephone replay will be
available until midnight, Aug. 30,
2010.
About Trubion
Trubion is a biopharmaceutical company that is creating a
pipeline of novel protein therapeutic product candidates to treat
autoimmune and inflammatory diseases and cancer. The Company's
mission is to develop a variety of first-in-class and best-in-class
product candidates, customized for optimal safety, efficacy and
convenience that it believes may offer improved patient
experiences. Trubion's current product candidates are novel
single-chain protein, or SMIP, therapeutics, and are designed using
its custom drug assembly technology. Trubion's product pipeline
includes CD20-directed SMIP therapeutics such as SBI-087 for
autoimmune and inflammatory diseases, developed under the Company's
Pfizer collaboration. Trubion's product pipeline also includes
TRU-016, a novel CD37-targeted therapy for the treatment of B-cell
malignancies developed under the Company's Facet collaboration. In
addition to Trubion's current clinical stage product pipeline, the
Company is also developing its multi-specific SCORPION technology,
both for targeting cell-surface molecules as well as simultaneously
neutralizing soluble ligands. More information is available in the
investors section of Trubion's website:
http://investors.trubion.com/index.cfm.
TRBN-G
Contact:
|
|
Jim DeNike
|
|
Senior Director, Corporate and
Marketing Communications
|
|
Trubion Pharmaceuticals,
Inc.
|
|
(206) 838-0500
|
|
jdenike@trubion.com
|
|
http://www.trubion.com
|
|
|
|
|
|
Waggener Edstrom Worldwide
Healthcare
|
|
Jenny Moede
|
|
Executive Vice
President
|
|
(503) 443-7507
|
|
jmoede@waggeneredstrom.com
|
|
|
SOURCE Trubion Pharmaceuticals, Inc.
Copyright . 13 PR Newswire